Resources

Advanced therapy medicinal products (ATMPs) is the buzzword that has been around the industry for a while now, with hopes to revolutionise the way medical treatments are done, hopefully moving away from 'traditional disease management' to cures.

Rentschler Biopharma is a leading company offering process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies.

The collaboration will improve visibility and reporting of cell and gene therapy manufacturing through a pre-integrated data solution

Symbiosis, a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.

Training provided by the University of Birmingham will focus on advanced therapy medicinal product (ATMP) manufacturing and clinical adoption First course to be launched September 2021 covering ATMPs and Good Manufacturing Practice (GMP)

RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter – announces the appointment of Peter Coleman as CEO.

RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

This new collaboration will deliver a powerful and innovative approach, to overcome barriers and form new companies that address current needs within the pioneering area of Advanced Therapy Medicinal Products (ATMPs).

The UK’s Cell and Gene Therapy Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its 2024 ATMP Clinical Trials Database.

Cell and gene therapies and tissue-engineered products have the potential to offer a durable, life-changing effect, possibly with single administration New report from Alliance for Regenerative Medicine and UK BioIndustry Association highlights progress in financing and clinical trials 24% of Europe’s ATMP developers headquartered in the UK

The last decade has seen significant scientific developments in cell therapies, gene therapies and tissue engineered products, collectively described as ATMPs (Advanced Therapy Medicinal Products). The impact of such treatments could be transformational. As such, we believe it is crucially important to support the sector as it navigates the complex clinical, regulatory, manufacturing, and pricing environments in which it operates.

Cell and gene therapies, otherwise known as advanced therapy medicinal products (ATMPs), have been developing quickly, revolutionising patient treatment across a range of conditions, but particularly leukaemia and lymphoma. That potential is now being realised across the disease landscape and the UK is playing a leading role in making that a reality.

The NIHR, Innovate UK, the Advanced Therapy Treatment Centre Network and the CGT Catapult announce a £17.9 million strategic initiative to enhance the UK environment for advanced therapy medicinal product (ATMP) clinical trials and to keep the UK as a location of choice for advanced therapy research.

In a week that will see a change of UK Prime Minister, I was delighted to be able to provide a positive and optimistic boost for the UK economy in launching a joint report with the Alliance of Regenerative Medicines, titled Leading Innovation: The UK’s ATMP landscape, which shows the UK’s globally leading position in advanced therapies, which includes the development of potentially transformative cell and gene therapies.

The UK BioIndustry Association (BIA) has welcomed today’s announcement that the NHS will be providing cell and gene therapies to treat patients with inherited retinal dystrophies.

Experts addressed different possible models for optimising data collection to support the adoption of cell and gene therapies in the UK. Barriers to digital integration, post-launch data collection and outcomes-based reimbursement were the primary focus of the day.

Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.